The standard method of determining fetal presentation, with an obstetrician palpitating the pregnant patient's abdomen, can miss up to 30% of breech births
According to an Australian study, a physical exam is not sensitive enough to detect abnormal fetal presentations in some patients and doctors should consider conducting an ultrasound scan in late pregnancy in difficult-to-assess cases. Breech presentations, which have a frequency of 3-4 %, and rarer transverse and oblique presentations, can make vaginal delivery difficult or impossible.
Lead author Natasha Nassar, comments that "Knowing that a baby is breech before labor begins means that the mother and her doctor have a choice about delivery options. They can consider the option of an external cephalic version (ECV) to turn the baby or plan for an elective cesarean section."
ECV is best carried out at 37 weeks gestation so timely detection of breech presentation is vital. If breech presentation is not diagnosed until after labour has begun, an emergency cesarean is required, which is known to increase the risk of adverse maternal and fetal outcomes, including death, compared with both vaginal birth and elective cesarean.
In this study, conducted by researchers at the University of Sydney, 1633 women with singleton pregnancies were examined late in pregnancy by an obstetrician, who was asked to identify the presentation of the fetus. The diagnosis was then confirmed by ultrasound scan.
Clinical exam by an obstetrician identified 70% of breech presentations. If these findings were applied to a population of 1000 pregnant women from the general population, physical examination would identify 101 women as having a breech or other abnormal presentation but in only 56 would this be correct; and 24 women with abnormal presentation would remain undetected.
Obstetricians were more likely to miss abnormal presentations in overweight women or first-time pregnancies. "For particularly overweight or obese women, an ultrasound in late pregnancy would be beneficial for these difficult-to-assess cases," recommended Dr Nassar.
Commenting on the study, Charles Lockwood of Yale Medical School (CA, USA) stated "We have long known that obstetrical caregivers are better able to detect breech presentations in thin women and those with multiple prior babies. However, given population trends toward obesity and fewer children, it is not surprising that the study suggests we do a poor job of detecting breech babies by physical examination -missing 30% of cases."
"The bottom line is that obstetrical-care providers who have office ultrasound machines would be wise to double-check fetal position at 35-37 weeks with a limited ultrasound examination," Dr Lockwood suggests. Following the US FDA's controversial rejection of Barr Pharmaceuticals' bid to make the 'morning after pill' Plan B ® available for purchase at US pharmacies, the company has amended its plans to include only women over the age of 18 years. The original proposal would have allowed pharmacists to supply the drug to over-16s.
Barr claims that making Plan B available without prescription would allow women to obtain the drug more quickly after unprotected sex, lowering the chance of an unwanted pregnancy.
The original application was made in 2003, but was rejected as the FDA felt that there was not sufficient evidence of its safety in girls aged 16 and younger, despite an expert panel deciding in favor of the move to easier access. The issue has become politically and emotionally charged, causing the resignation of a top FDA women's health official who felt that the decision was made for political rather than medical reasons.
The FDA recently stated that it hopes to make a final decision 'within weeks'. Source: www.fda.gov 
in brief…
Cost-effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding.
Brown PM, Farquhar CM, Lethaby A, Sadler LC, Johnson NP: BJOG 113 (7), 797-803 (2006) .
Compares the cost-effectiveness of the levonorgestrel intrauterine system and thermal balloon ablation for the treatment of heavy periods. A total of 79 women with heavy menstrual bleeding were randomized to each intervention and the cost-effectiveness of the treatments examined by economic analysis. Both treatments improved quality of life but the levonorgestrel intrauterine system was more cost-effective.
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. Examines the effect of chest x-rays on women with BRCA1/2 mutations. Exposure to ionizing radiation is a known risk factor for breast cancer and the investigators suspected that, since BRCA proteins are involved in DNA repair, BRCA carriers would be more suspectible to this risk. In a cohort of 1601 female BRCA1/2 carriers, any reported exposure to chest x-rays increased the risk of breast cancer by 54%. Women under the age of 40 had a 97% increased risk and those exposed to chest x-rays before the age of 20 years only had a fourfold increased risk.
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
The Arimidex, Tamoxifen, Alone or in Combination Trialists' Group; Buzdar A, Howell A, Cuzick J et al. : Lancet Oncol. 7(8) , 633-643 (2006) .
Demonstrates that anastrozole is better tolerated and has a lower recurrence rate than tamoxifen when used to treat postmenopausal women with early breast cancer. Over 6000 eligible women were randomized to receive either tamoxifen or anastrazole for 5 years. Women receiving anastrozole had a lower incidence of adverse effects, a better risk-benefit ratio and a lower rate of recurrence.
Daughters of women who received DES during pregnancy may be at greater risk of breast cancer
During the 1940s, 50s and 60s millions of pregnant women were prescribed diethylstilbestrol (DES) to prevent miscarriage. The drug was withdrawn in 1971 after studies showed that the drug could interfere with the development of the reproductive system of the fetus.
Women who received DES during pregnancy are themselves at slightly increased risk of breast cancer, but it was not known if this risk was present in the women exposed in utero to the drug. Exposed daughters do have an increased risk of rare clear cell adenocarcinoma of the cervix or vagina.
In this study, researchers followed 4817 women who had been exposed to DES in the womb, and 2073 matched women who had not, for 22-24 years. After adjusting for other risk factors, women over the age of 40 years who had been exposed in utero were twice as likely to develop breast cancer as nonexposed women of the same age. It appeared that this risk increased with age, although the number of women involved was too small to achieve statistical significance.
Women who know they were exposed to this drug in the womb should be sure to attend their scheduled mammograms and clinical breast exams, and maintain a healthy lifestyle. The authors, led by Julie Palmer, also suggest that these women avoid postmenopausal hormone therapy: "Because the commonly used female hormone supplements have been shown to independently increase risk of breast cancer, it might be wise for exposed women to avoid such supplements whenever possible." 
Taking vitamin supplements before conception may reduce risk of preeclampsia
Women who take vitamin supplements at least once a week before conception and during the first trimester were significantly less likely to suffer preeclampsia, according to a study published recently in the American Journal of Epidemiology. A total of 1835 pregnant women at under 16 weeks' gestation were asked to recall whether they had regularly used vitamin supplements in the last 6 months.
"Our data show that women who are not overweight before pregnancy and who used multivitamins at least once a week before conception and in the first three months of pregnancy reduced their risk of preeclampsia by a striking 71% compared to those who didn't take a multivitamin during this time period," enthused lead author Lisa Bodnar, University of Pittsburgh (PA, USA).
"At this time, multivitamin use makes little apparent difference in preeclampsia rates for women who are overweight before pregnancy. Even so, the results suggest that regular multivitamin use in the prepregnancy period may help to prevent preeclampsia" she continued.
The authors emphasize that these findings need to be confirmed by larger, more rigorous studies, but suggest that as a cheap and readily available intervention, vitamin supplements have potential as a preventative measure for preeclampsia. 
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Fenretinide has potential for premenopausal breast cancer prevention
Fenretinide appears to lower the risk of breast cancer recurrence by 50% in women aged 40 years or under, but has no effect in those aged over 55 years.
A study published recently in the Annals of Oncology suggests that fenretinide, a vitamin A derivative, has promise in preventing the recurrence of breast cancer in younger women.
The study involved 1739 women with early stage breast cancer who had undergone surgery and in some cases radiotherapy. Approximately half of the women were assigned to receive 200 mg fenretinide daily for 5 years, while the other half served as a control group. The large capsule size and length of treatment meant that a placebo group was not feasible. There was a mean follow up of 14.6 years and the primary end point was a diagnosis of contralateral or ipsilatreal breast cancer.
Overall there was a 17% reduction in breast cancer recurrence in the group receiving fenretinide. Premenopausal women accounted for almost all of this difference, with a 38% decrease in events. Postmenopausal women had no significant decrease in risk. The researchers conclude that "The current analysis confirms and further extends the notion that the protective effect of fenretinide occurs exclusively in premenopausal women aged 55 years or younger." This protective effect appears to be present regardless of the hormone-receptor status of the tumor.
However, the investigators, led by Umberto Veronesi, stress that the results are "are hypothesis-generating and do not have practical implications." The author of an accompanying editorial, Kathy Pritchard of Toronto University (Canada), re-iterated this point, stating that "fenretinide is not ready yet for prime time, and I would not recommend using this drug for breast cancer prevention."
The side-effect profile of the drug was acceptable with a drop-out rate of 4.4%. Other vitamin A (retinol) derivatives are teratogenic and, while no such effect was observed with fenretinide in animal studies, reliable contraception will be necessary if this drug is to be used in women of childbearing age. Source: Veronesi U, Mariani L, Decensi A et. al.: Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
Ann. Oncol. 17, 1035 Oncol. 17, -1036 Oncol. 17, (2006 .
Pregnant epileptics should avoid valproate if possible
The antiepileptic valproate is associated with a 20% rate of severe fetal adverse outcomes in pregnant patients, according to results from a study involving 333 pregnant epileptic women
The women, each of whom was receiving a single antiepileptic drug, were selected from 25 centers in the USA and UK between 1999 and 2004. A total of 110 women were receiving carbamazepine, 98 lamotrigine, 56 phenytoin and 69 valproate.
As lead author Kimford Meador points out, the trial was not originally designed to look at birth defects. "We wanted to look at the impact of these drugs on neurodevelopmental later in life," Dr Meador comments. "Then the early effects came to light."
Two fetal losses and 12 cases of congenital malformations were identified in the offspring of women receiving valproate. The rates of severe adverse events in the fetus were 20.3% for valproate, 10.7% for phenytoin, 8.2% for carbamazepine and 1.0% for lamotrigine.
The malformations in affected babies were diverse, including skull deformities, cleft palate, heart structural abnormalities and kidney swelling due to backup of urine.
"My personal view is that valproate should not be used as the first therapy in pregnant women," stated Dr Meador.
However, for women who must use valproate, "their doctor should emphasize that despite the increased risk of adverse outcomes, the majority of pregnant women who take the drug have normal, healthy babies." 
Morning labor induction may be preferable
When labor needs to be induced it should be done in the morning, according to a study by researchers at the University of Adelaide (Australia).
A total of 620 women scheduled for induced labor were randomized to be admitted at either 8 am or 10 pm. The main end points (the number of women who were in labor beyond 24 h, uterine hyperstimulation, and fetal heart rate changes or cesarean deliveries) showed no difference between morning or evening induction. However, women induced in the morning were less likely to require operative vaginal birth or an infusion of the hormone oxytocin.
"It is unclear if these findings reflect physiological differences, or whether it reflects differences in clinical practice that may occur by staff during the day and during the night," commented Jodie Dodd and colleagues.
Source: Dodd JM, Crowther CA, Robinson JS:
Morning compared with evening induction of labor: a nested randomized controlled trial.
Obstet. Gynecol. 108(2), 350-360 (2006) .
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